Cargando…
Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells
Recurrence and metastasis are the two leading causes of poor prognosis in patients with hepatocellular carcinoma (HCC). Secreted clusterin (sCLU) is a stress-induced chaperone that is overexpressed in HCC. However, the precise molecular mechanisms of sCLU in HCC invasion and migration are largely un...
Autores principales: | Zhong, Jingtao, Yu, Xiaoming, Dong, Xiaofeng, Lu, Hong, Zhou, Wuyuan, Li, Lei, Li, Zhongchao, Sun, Pengfei, Shi, Xuetao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920948/ https://www.ncbi.nlm.nih.gov/pubmed/29731881 http://dx.doi.org/10.3892/ol.2018.8186 |
Ejemplares similares
-
Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma
por: Zhou, Yinghong, et al.
Publicado: (2020) -
T7 peptide cytotoxicity in human hepatocellular carcinoma cells is mediated by suppression of autophagy
por: Liu, Feng, et al.
Publicado: (2019) -
Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma
por: Wang, Xin, et al.
Publicado: (2018) -
Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma
por: Zhang, Bo, et al.
Publicado: (2022) -
Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target
por: Zheng, Wenjie, et al.
Publicado: (2016)